title: Motivational groups support adherence to antiretroviral therapy and use of risk reduction behaviors in HIV positive Nigerian women: a pilot study.
abstract: Nigerian women comprise the fastest growing group of persons with AIDS in Africa. Antiretroviral therapy has transformed the course of HIV/AIDS to a treatable, chronic illness worldwide. The purpose of this pilot study was to assess the efficacy of a group intervention using motivational interviewing (MI) to promote adherence to antiretroviral therapy (ART) and use of risk reduction behaviors (RRB) among HIV-infected women in Nigeria. Recruited participants (n=60) were randomly assigned to the motivational group or the health promotion program (HPP) control group. The 6 month follow-up results indicate that, compared to the control group, MI participants reported significantly higher levels of adherence to ART, higher knowledge of HIV, higher use of condoms/protection during sexual encounters and decision-making not to have sex when no protection was available. The MI participants also had fewer mean number of sexual partners. MI in group format shows promise in promoting adherence to ART and use of RRB in HIV-infected Nigerian women.
authors: Nell Hodgson School of Nursing, Emory University, USA. nurmmcd@emory.edu
authors: Marcia McDonnell
authors: MM
authors: Holstad
authors: James E
authors: JE
authors: Essien
authors: Ernest
authors: E
authors: Ekong
authors: Melinda
authors: M
authors: Higgins
authors: Ilya
authors: I
authors: Teplinskiy
authors: Modupe Falilatu
authors: MF
authors: Adewuyi
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity / Q000628:therapy*; D006293:Health Promotion; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D062405:Motivational Interviewing / Q000379:methods; D010349:Patient Compliance; D010865:Pilot Projects; D040242:Risk Reduction Behavior; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents